title: Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens.
abstract: OBJECTIVE
  to describe the impact of tenofovir disoproxil fumarate (TDF) use on renal function in HIV-infected pediatric patients.
  
  
  METHODS
  it is a prospective, multicenter study. The setting consisted of five third-level pediatric hospitals in Spain. The study was conducted on patients aged 18 years and younger who had received TDF for at least 6 months. The intervention was based on the study of renal function parameters by urine and serum analyses. The main outcome measures were renal function results following at least 6 months of TDF therapy.
  
  
  RESULTS
  forty patients were included (32 were white and 26 were diagnosed with AIDS). Median (range) duration of TDF treatment was 77 months (16-143). There were no significant changes in the estimated creatinine clearance. Urine osmolality was abnormal in eight of 37 patients, a decrease in tubular phosphate absorption was documented in 28 of 38 patients, and 33 of 37 patients had proteinuria. A statistically significant decrease in serum phosphate and potassium concentrations was observed during treatment (P = 0.005 and P = 0.003, respectively), as well as a significant relationship between final phosphate concentration and tubular phosphate absorption (P = 0.010). A negative correlation was found between phosphate concentration and time on TDF.
  
  
  CONCLUSIONS
  TDF use showed a significant association with renal tubular dysfunction in HIV-infected pediatric patients. Periodic assessment of tubular function may be advisable in the follow-up of this population.
authors.affiliation: Pediatric Infectious Diseases and Immunodeficiencies Unit, Vall d'Hebron University Hospital, Spain. psoler@vhebron.net
authors.forename: Pere
authors.initials: P
authors.lastname: Soler-Palacín
authors.forename: Susana
authors.initials: S
authors.lastname: Melendo
authors.forename: Antoni
authors.initials: A
authors.lastname: Noguera-Julian
authors.forename: Claudia
authors.initials: C
authors.lastname: Fortuny
authors.forename: María L
authors.initials: ML
authors.lastname: Navarro
authors.forename: María J
authors.initials: MJ
authors.lastname: Mellado
authors.forename: Lourdes
authors.initials: L
authors.lastname: Garcia
authors.forename: Sonia
authors.initials: S
authors.lastname: Uriona
authors.forename: Andrea
authors.initials: A
authors.lastname: Martín-Nalda
authors.forename: Concepció
authors.initials: C
authors.lastname: Figueras
mesh_terms: D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000293:Adolescent; D023241:Antiretroviral Therapy, Highly Active; D002648:Child; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000378:metabolism; D007677:Kidney Function Tests; D008297:Male; D063065:Organophosphonates / Q000009:adverse effects*; D011446:Prospective Studies; D011507:Proteinuria / Q000139:chemically induced* / Q000378:metabolism; D013030:Spain; D000068698:Tenofovir
chemical_list: D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine